Mitochondrial Diseases: Clinical Trials

46 trials for Mitochondrial Diseases, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

25 completed, 7 recruiting, 5 active not recruiting, 4 terminated. 46 Phase 3, 7 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 346Completed 25, Recruiting 7, Active not recruiting 5, Terminated 4, Not yet recruiting 2, Withdrawn 2, Unknown 1
Phase 27Completed 2, Terminated 2, Active not recruiting 1, Recruiting 1, Unknown 1

Follow Mitochondrial Diseases: new trials by email Literature Review of Mitochondrial Diseases trials Research Report on Mitochondrial Diseases

Trials (filtered) newest first · largest first

All 46 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Efficacy and Safety of Modafinil to Treat Fatigue in People With Mitochondrial Disease.
Modafinil (M), Placebo - Mitochondrial Disease
Phase 3Not yet recruitingKenneth Myers, MD152026-12-012026-10-26
A Study to Evaluate the Efficacy and Safety of Subcutaneous Nomlabofusp in Subjects With Friedreich's Ataxia
Nomlabofusp, Placebo - Friedreich Ataxia, Friedreich's Ataxia
Phase 3RecruitingLarimar Therapeutics, Inc.1502026-10-262026-10-09
Long-Term Efficacy Study of Vatiquinone for the Treatment of Friedreich's Ataxia (FA)
Vatiquinone - Friedreich's Ataxia
Phase 3Not yet recruitingPTC Therapeutics1202026-08-152026-08-14
KHENERFIN Study: A Trial to Evaluate the Efficacy and Safety of Sonlicromanol in Primary Mitochondrial Diseases
Sonlicromanol, Placebo - Mitochondrial Diseases, Maternally Inherited Diabetes and Deafness (MIDD)
Phase 3RecruitingKhondrion BV2202026-04-142026-10-14
A Study to Learn More About the Effects and Long-Term Safety of Omaveloxolone (BIIB141) in Children and Teens With Friedreich's Ataxia
Omaveloxolone, Placebo - Friedreich Ataxia
Phase 3Active not recruitingBiogen2552025-06-092026-10-02
Study to Evaluate Sepofarsen in Subjects With Leber Congenital Amaurosis (LCA) Type 10 (HYPERION)
sepofarsen, Placebo IVT - Leber Congenital Amaurosis 10, Blindness
Phase 3RecruitingLaboratoires Thea322025-06-042026-10-21
A Phase 3, Multicenter, Randomized, Double-Masked, Sham-Controlled Clinical Trial for Leber's Hereditary Optic Neuropathy (LHON) Associated With ND4 Mutation
rAAV2-ND4, Sham (No Treatment) - Leber Hereditary Optic Neuropathy (LHON)
Phase 3Active not recruitingWuhan Neurophth Biotechnology Limited Company952024-09-192026-02-12
Coenzyme Q10 for Gulf War Illness: A Replication Study
PharmaNord Bio-Quinone Active CoQ10 Gold 100mg, PharmaNord Placebo - Gulf War Syndrome, Persian Gulf Syndrome
Phase 3RecruitingUniversity of California, San Diego1922024-09-132026-05-01
CoQ10 and Exercise for Mitochondrial Dysfunction in Advance Kidney Disease
CoQ10, Placebo, HB-HIIT - End Stage Renal Disease
Phase 3RecruitingVanderbilt University Medical Center1562023-06-012026-01-02
A Study to Assess the Safety and Efficacy of Vatiquinone in Participants With Friedreich Ataxia
Vatiquinone - Friedreich Ataxia
Phase 3Active not recruitingPTC Therapeutics1302022-12-082025-10-30
A Study of the Efficacy and Safety of MT1621 in Thymidine Kinase 2 (TK2) Deficiency (Treatment naïve)
MT1621 - Thymidine Kinase 2 Deficiency
Phase 3WithdrawnZogenix MDS, Inc.2022-09-302023-09-01
A Safety Study for Previously Treated Vatiquinone (PTC743) Participants With Inherited Mitochondrial Disease
Vatiquinone - Inherited Mitochondrial Disease
Phase 3CompletedPTC Therapeutics1012022-06-222025-12-22
Study to Evaluate Efficacy and Safety of Elamipretide in Subjects With Primary Mitochondrial Disease From Nuclear DNA Mutations (nPMD)
Elamipretide, Placebo - Mitochondrial Myopathies, Mitochondrial Pathology
Phase 3CompletedStealth BioTherapeutics Inc.1022022-04-292025-10-24
Idebenone for the Preventive Treatment of Migraine
Placebo, 90mg Idebenone, 270mg Idebenone - Migraine Disorders, Headache Disorders
Phase 3RecruitingSecond Affiliated Hospital, Zhejiang University, School of Medicine1802021-12-082025-05-15
Gene Therapy Clinical Trial for the Treatment Of Leber's HereDitary Optic Neuropathy
NR082 injection, Sham Injection - Leber's Hereditary Optic Neuropathy (LHON)
Phase 2 / Phase 3RecruitingWuhan Neurophth Biotechnology Limited Company1022021-06-182022-11-14
A Study to Assess the Efficacy and Safety of Vatiquinone for the Treatment of Participants With Friedreich Ataxia
Vatiquinone, Placebo - Friedreich Ataxia
Phase 2 / Phase 3CompletedPTC Therapeutics1462020-12-172026-04-13
A Study to Evaluate Efficacy and Safety of Vatiquinone for Treating Mitochondrial Disease in Participants With Refractory Epilepsy
Vatiquinone, Placebo - Mitochondrial Diseases, Drug Resistant Epilepsy
Phase 2 / Phase 3TerminatedPTC Therapeutics682020-09-282026-03-31
Trial of Dichloroacetate in Pyruvate Dehydrogenase Complex Deficiency:
Dichloroacetate (DCA), Placebo, Genotype - Pyruvate Dehydrogenase Complex Deficiency
Phase 3Active not recruitingSaol Therapeutics Inc342020-07-142025-05-04
A Study to Assess Efficacy, Long Term Safety and Tolerability of RT001 in Subjects With Friedreich's Ataxia
RT001, Placebo - Friedreich's Ataxia
Phase 3CompletedBiojiva LLC652019-10-302022-05-27
A Study to Evaluate Efficacy, Safety, Tolerability and Exposure After a Repeat-dose of Sepofarsen (QR-110) in LCA10 (ILLUMINATE)
sepofarsen, Sham - Leber Congenital Amaurosis 10, Blindness
Phase 2 / Phase 3Active not recruitingProQR Therapeutics362019-04-042022-03-17

Showing 20 of 46. Sign in to see all of them.

Narrower conditions

Friedreich Ataxia (16)  ·  Optic Atrophy, Hereditary, Leber (11)  ·  Eye Diseases (6)  ·  Eye Diseases, Hereditary (6)  ·  Multiple Acyl Coenzyme A Dehydrogenase Deficiency (5)  ·  Cytomegalovirus Infections (4)  ·  HIV Infections (4)  ·  Acquired Immunodeficiency Syndrome (3)  ·  Cytomegalovirus Retinitis (3)  ·  Genetic Diseases, Inborn (3)  ·  MELAS Syndrome (3)  ·  Nervous System Diseases (3)  ·  Neurodegenerative Diseases (3)  ·  Retinitis (3)

Broader conditions

Metabolic Diseases (46)  ·  Nutritional and Metabolic Diseases (46)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (37)  ·  Genetic Diseases, Inborn (34)  ·  Nervous System Diseases (33)  ·  Heredodegenerative Disorders, Nervous System (29)  ·  Neurodegenerative Diseases (25)  ·  Brain Diseases (22)  ·  Central Nervous System Diseases (22)  ·  Cerebellar Diseases (16)  ·  Spinal Cord Diseases (16)  ·  Spinocerebellar Degenerations (16)  ·  Cranial Nerve Diseases (12)  ·  Optic Atrophy (11)

Interventions

idebenone (6)  ·  alpha-tocotrienol quinone (5)  ·  Ganciclovir (4)  ·  interferon gamma-1b (3)  ·  salicylhydroxamic acid (3)  ·  Valganciclovir (2)  ·  Allopurinol (1)  ·  Creatine (1)  ·  Curcumin (1)  ·  Deoxycytidine (1)  ·  Dichloroacetic Acid (1)  ·  Exercise (1)  ·  Genotype (1)  ·  Glucose (1)  ·  Magnesium Oxide (1)

Sponsors

PTC Therapeutics (5)  ·  Santhera Pharmaceuticals (5)  ·  GenSight Biologics (4)  ·  Amgen (3)  ·  National Institute of Allergy and Infectious Diseases (NIAID) (3)  ·  Wuhan Neurophth Biotechnology Limited Company (2)  ·  Assistance Publique - Hôpitaux de Paris (1)  ·  Biogen (1)  ·  Biojiva LLC (1)  ·  Hospices Civils de Lyon (1)  ·  Huazhong University of Science and Technology (1)  ·  Kenneth Myers, MD (1)  ·  Khondrion BV (1)  ·  Laboratoires Thea (1)  ·  Larimar Therapeutics, Inc. (1)

Countries

United States (31)  ·  France (16)  ·  Germany (13)  ·  Italy (13)  ·  United Kingdom (13)  ·  Canada (10)  ·  Spain (10)  ·  Netherlands (7)  ·  Australia (6)  ·  Brazil (6)  ·  Belgium (5)  ·  Austria (4)  ·  China (4)  ·  New Zealand (4)  ·  Denmark (2)

Top investigators

David Lynch, MD (2)  ·  Nancy Newman, MD (2)  ·  Susan Perlman, MD (2)  ·  Vinay Penematsa, MD (2)  ·  Adolfo D. Rodriguez-Carrizalez, PhD (1)  ·  Annette S. Feigenbaum, MD (1)  ·  Baback Roshanravan, MD/MPH (1)  ·  Beatrice A Golomb, MD, PhD (1)  ·  Bin Li, MD (1)  ·  Bin Li, PhD,MD (1)  ·  David A. Wohl, MD (1)  ·  Diana Rosas, MD, MS (1)  ·  Douglas S. Kerr, MD, PhD (1)  ·  Feinberg J (1)

Results publications

PMID 36449262, PMID 34108929, PMID 21779958, PMID 11972582, PMID 1463007, PMID 1674640, PMID 18441370, PMID 18441371, PMID 18774912, PMID 1928099, PMID 19632953, PMID 20065258, PMID 20697044, PMID 21392622, PMID 21586650, PMID 21788663, PMID 22612072, PMID 22644094, PMID 23063736, PMID 24396955, PMID 25916335, PMID 25950380, PMID 26321318, PMID 26606867, PMID 26892229, PMID 27386292, PMID 27426279, PMID 27749593, PMID 28132202, PMID 28701493, PMID 29298622, PMID 30103342, PMID 31237206, PMID 31495483, PMID 3201231, PMID 33451738, PMID 35747889, PMID 39699886, PMID 5063796

NIH funding

2015 (2), 2017 (2), 2025 (2), 2018 (1), U01AT000613 (1)